Search

Your search keyword '"Coviello, E."' showing total 118 results
Start Over Author "Coviello, E."
118 results on '"Coviello, E."'

1. Early CAR- CD4+ T-lymphocytes recovery following CAR-T cell infusion: A worse outcome in diffuse large B cell lymphoma

Author

Gambella, M, Carlomagno, S, Mangerini, R, Colombo, N, Parodi, A, Ghiggi, C, Giannoni, L, Coviello, E, Setti, C, Luchetti, S, Serio, A, Laudisi, A, Passannante, M, Bo, A, Tedone, E, Sivori, S, Angelucci, E, Raiola, A, Raiola, AM, Gambella, M, Carlomagno, S, Mangerini, R, Colombo, N, Parodi, A, Ghiggi, C, Giannoni, L, Coviello, E, Setti, C, Luchetti, S, Serio, A, Laudisi, A, Passannante, M, Bo, A, Tedone, E, Sivori, S, Angelucci, E, Raiola, A, and Raiola, AM

Abstract

CAR(-) CD4(+) T cell lymphopenia is an emerging issue following CAR-T cell therapy. We analyzed the determinants of CD4(+) T cell recovery and a possible association with survival in 31 consecutive patients treated with commercial CAR-T for diffuse large B-cell (DLBCL) or mantle cell lymphoma. Circulating immune subpopulations were characterized through multiparametric-flow cytometry. Six-month cumulative incidence of CAR(- )CD4(+) T cell recovery (>= 200 cells/mu L) was 0.43 (95% confidence interval [CI]: 0.28-0.65). Among possible determinants of CD4(+) T cell recovery, we recognized infusion of a 4-1BB product (tisagenlecleucel, TSA) in comparison with a CD28 (axicabtagene/brexucabtagene, AXI/BRX) (hazard ratio [HR] [95% CI]: 5.79 [1.16-24.12] p = 0.016). Higher CD4(+) T cell counts resulted with TSA at month-1, -2 and -3. Moderate-to-severe infections were registered with prolonged CD4(+) T cell lymphopenia. Early, month-1 CD4(+ )T cell recovery was associated with a worse outcome in the DLBCL cohort, upheld in a multivariate regression model for overall survival (HR: 4.46 [95% CI: 1.12-17.71], p = 0.03). We conclude that a faster CAR(- )CD4(+) T cell recovery is associated with TSA as compared to AXI/BRX. Month-1 CAR(-) CD4(+) T cell subset recovery could represent a "red flag" for CAR-T cell therapy failure in DLBCL patients.

Published
2024

2. SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort

Author

Merli, M, Ferrarini, I, Merli, F, Busca, A, Mina, R, Falini, B, Bruna, R, Cairoli, R, Marchetti, M, Romano, A, Cavo, M, Arcaini, L, Trentin, L, Cattaneo, C, Derenzini, E, Fracchiolla, N, Marchesi, F, Scattolin, A, Billio, A, Bocchia, M, Massaia, M, Gambacorti-Passerini, C, Mauro, F, Gentile, M, Mohamed, S, Della Porta, M, Coviello, E, Cilloni, D, Visani, G, Federici, A, Tisi, M, Cudillo, L, Galimberti, S, Gherlinzoni, F, Pagano, L, Guidetti, A, Bertu, L, Corradini, P, Passamonti, F, Visco, C, Merli M., Ferrarini I., Merli F., Busca A., Mina R., Falini B., Bruna R., Cairoli R., Marchetti M., Romano A., Cavo M., Arcaini L., Trentin L., Cattaneo C., Derenzini E., Fracchiolla N. S., Marchesi F., Scattolin A., Billio A., Bocchia M., Massaia M., Gambacorti-Passerini C., Mauro F. R., Gentile M., Mohamed S., Della Porta M. G., Coviello E., Cilloni D., Visani G., Federici A. B., Tisi M. C., Cudillo L., Galimberti S., Gherlinzoni F., Pagano L., Guidetti A., Bertu L., Corradini P., Passamonti F., Visco C., Merli, M, Ferrarini, I, Merli, F, Busca, A, Mina, R, Falini, B, Bruna, R, Cairoli, R, Marchetti, M, Romano, A, Cavo, M, Arcaini, L, Trentin, L, Cattaneo, C, Derenzini, E, Fracchiolla, N, Marchesi, F, Scattolin, A, Billio, A, Bocchia, M, Massaia, M, Gambacorti-Passerini, C, Mauro, F, Gentile, M, Mohamed, S, Della Porta, M, Coviello, E, Cilloni, D, Visani, G, Federici, A, Tisi, M, Cudillo, L, Galimberti, S, Gherlinzoni, F, Pagano, L, Guidetti, A, Bertu, L, Corradini, P, Passamonti, F, Visco, C, Merli M., Ferrarini I., Merli F., Busca A., Mina R., Falini B., Bruna R., Cairoli R., Marchetti M., Romano A., Cavo M., Arcaini L., Trentin L., Cattaneo C., Derenzini E., Fracchiolla N. S., Marchesi F., Scattolin A., Billio A., Bocchia M., Massaia M., Gambacorti-Passerini C., Mauro F. R., Gentile M., Mohamed S., Della Porta M. G., Coviello E., Cilloni D., Visani G., Federici A. B., Tisi M. C., Cudillo L., Galimberti S., Gherlinzoni F., Pagano L., Guidetti A., Bertu L., Corradini P., Passamonti F., and Visco C.

Abstract

COVID-19, the disease caused by SARS-CoV-2, is still afflicting thousands of people across the globe. Few studies on COVID-19 in chronic lymphocytic leukemia (CLL) are available. Here, we analyzed data from the CLL cohort of the Italian Hematology Alliance on COVID-19 (NCT04352556), which included 256 CLL patients enrolled between 25 February 2020 and 1 February 2021. Median age was 70 years (range 38–94) with male preponderance (60.1%). Approximately half of patients (n = 127) had received at least one line of therapy for CLL, including 108 (83.7%) who were on active treatment at the time of COVID-19 or received their last therapy within 12 months. Most patients (230/256, 89.9%) were symptomatic at COVID-19 diagnosis and the majority required hospitalization (n = 176). Overall, after a median follow-up of 42 days (IQR 24–96), case fatality rate was 30.1%, and it was 37.5% and 24.4% in the first (25 February 2020–22 June 2020) and second wave (23 June 2020–1 February 2021), respectively (p = 0.03). At multivariate analysis, male sex (HR 1.82, 95% CI 1.03–3.24, p = 0.04), age over than 70 years (HR 2.23, 95% CI 1.23–4.05, p = 0.01), any treatment for CLL given in the last 12 months (HR 1.72, 95% CI 1.04–2.84, p = 0.04) and COVID-19 severity (severe: HR 5.66, 95% CI 2.62–12.33, p < 0.0001; critical: HR 15.99, 95% CI 6.93–36.90, p < 0.0001) were independently associated with poor survival. In summary, we report a dismal COVID-related outcome in a significant fraction of CLL patients, that can be nicely predicted by clinical parameters.

Published
2023

3. Late Mortality, Subsequent Malignant Neoplasms and Hospitalisations in Long-Term Survivors of Adolescent and Young Adult Hematological Cancers

Author

Trama, A, Vener, C, Lasalvia, P, Bernasconi, A, Zorzi, M, Andreano, A, Contiero, P, Manneschi, G, Falcini, F, Castaing, M, Filiberti, R, Gasparotti, C, Cirilli, C, Amodio, R, Bisceglia, I, Iacovacci, S, Vitale, M, Stracci, F, Gentilini, M, Tumino, R, Carone, S, Sampietro, G, Melcarne, A, Gatti, L, Boschetti, L, Corti, M, Rognoni, M, Coviello, E, Pesce, M, D'Orsi, G, Fanetti, A, De Lorenzis, L, Candela, G, Savoia, F, Pascucci, C, Castelli, M, Storchi, C, Trama A., Vener C., Lasalvia P., Bernasconi A., Zorzi M., Andreano A., Contiero P., Manneschi G., Falcini F., Castaing M., Filiberti R. A., Gasparotti C., Cirilli C., Amodio R., Bisceglia I., Iacovacci S., Vitale M. F., Stracci F., Gentilini M. A., Tumino R., Carone S., Sampietro G., Melcarne A., Gatti L., Boschetti L., Corti M., Rognoni M., Coviello E., Pesce M. T., D'Orsi G., Fanetti A. C., De Lorenzis L., Candela G., Savoia F., Pascucci C., Castelli M., Storchi C., Trama, A, Vener, C, Lasalvia, P, Bernasconi, A, Zorzi, M, Andreano, A, Contiero, P, Manneschi, G, Falcini, F, Castaing, M, Filiberti, R, Gasparotti, C, Cirilli, C, Amodio, R, Bisceglia, I, Iacovacci, S, Vitale, M, Stracci, F, Gentilini, M, Tumino, R, Carone, S, Sampietro, G, Melcarne, A, Gatti, L, Boschetti, L, Corti, M, Rognoni, M, Coviello, E, Pesce, M, D'Orsi, G, Fanetti, A, De Lorenzis, L, Candela, G, Savoia, F, Pascucci, C, Castelli, M, Storchi, C, Trama A., Vener C., Lasalvia P., Bernasconi A., Zorzi M., Andreano A., Contiero P., Manneschi G., Falcini F., Castaing M., Filiberti R. A., Gasparotti C., Cirilli C., Amodio R., Bisceglia I., Iacovacci S., Vitale M. F., Stracci F., Gentilini M. A., Tumino R., Carone S., Sampietro G., Melcarne A., Gatti L., Boschetti L., Corti M., Rognoni M., Coviello E., Pesce M. T., D'Orsi G., Fanetti A. C., De Lorenzis L., Candela G., Savoia F., Pascucci C., Castelli M., and Storchi C.

Abstract

Background: Increased success in the treatment of hematological cancers contributed to the increase of 5-year survival for most adolescent and young adults (AYAs) with these tumours. However, as 5-year survival increased, it became clear that AYA long-term survivors were at increased risk for severe late effects. Moreover, limited information on long-term cancer impact is available for AYAs, since most studies focused on children and adolescents. We aimed to assess various long-term outcomes on AYA survivors of hematological cancers. Methods: We selected patients diagnosed with a first primary hematological cancer between 1997 and 2006, in the Italian nationwide population-based cohort of AYA cancer survivors (i.e. alive at least 5 years after cancer diagnosis). Long-term outcomes of interest were: second malignant neoplasms (SMNs), hospitalizations and overall mortality. We calculated standardized incidence ratios (SIRs), standardized hospitalization rate ratios (SHRs) and standardized mortality rate ratios (SMRs). To study morbidity patterns over time, we modeled observed incidence rates by fitting flexible parametric models for nonlinear patterns and we used linear regression for linear patterns. Results: The study cohort included 5,042 AYA hematological cancer survivors of which 1,237 and 3,805 had a leukaemia and lymphoma diagnosis, respectively. AYA survivors were at substantially increased risk for SMN (SIR=2.1; 95%CI=1.7; 2.6), hospitalisation (SHR=1.5; 95%CI=1.5; 1.6), and mortality (SMR=1.4; 95%CI=1.2; 1.6) with differences between leukaemia and lymphoma survivors. The highest excess risks of hospitalisations were for infectious diseases, respiratory diseases, and diseases of blood and blood-forming organs. The morbidity pattern differs over time by morbidity type. Conclusions: Our results support the need for strict follow-up plans for survivors, and call for further study to better personalised follow-up plans for AYA cancer survivors.

Published
2022

4. Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV

Author

Zappasodi, P, Cattaneo, C, Ferretti, V, Mina, R, Ferreri, A, Merli, F, Oberti, M, Krampera, M, Romano, A, Zerbi, C, Ferrari, J, Cavo, M, Marco Salvini, M, Bertù, L, Fracchiolla, N, Marchesi, F, Massaia, M, Marasco, V, Cairoli, R, Scattolin, A, Vannucchi, A, Gambacorti-Passerini, C, Musto, P, Gherlinzoni, F, Cuneo, A, Pinto, A, Trentin, L, Bocchia, M, Galimberti, Coviello, E, Mc, Morotti, A, Falini, B, Turrin, M, Tafuri, A, Billio, A, Gentile, M, Lemoli, M, 37, Venditti, A, Della Porta, M, Lanza, F, Rigacci, L, Tosi, P, Mohamed, S, Corso, A, Luppi, M, Giuliani, N, Busca, A, Pagano, L, Bruno, R, Grossi, P, Corradini, P, Passamonti, F, Arcaini, L, Zappasodi P, Cattaneo C, Ferretti V, Mina R, Ferreri AJ, Merli F, Oberti M, Krampera M, Romano A, Zerbi C, Ferrari J, Cavo M, Marco Salvini M, Bertù L, Fracchiolla N, Marchesi F, Massaia M, Marasco V, Cairoli R, Scattolin AM, Vannucchi AM, Gambacorti-Passerini C, Musto P, Gherlinzoni F, Cuneo A, Pinto A, Trentin L, Bocchia M, Coviello E, MC, Morotti A, Falini B, Turrin M, Tafuri A, Billio A, Gentile M, Lemoli M, Venditti A, Della Porta M, Lanza F, Rigacci L, Tosi P, Mohamed S, Corso A, Luppi M, Giuliani N, Busca A, Pagano L, Bruno R, Grossi P, Corradini P, Passamonti F, Arcaini L., Zappasodi, P, Cattaneo, C, Ferretti, V, Mina, R, Ferreri, A, Merli, F, Oberti, M, Krampera, M, Romano, A, Zerbi, C, Ferrari, J, Cavo, M, Marco Salvini, M, Bertù, L, Fracchiolla, N, Marchesi, F, Massaia, M, Marasco, V, Cairoli, R, Scattolin, A, Vannucchi, A, Gambacorti-Passerini, C, Musto, P, Gherlinzoni, F, Cuneo, A, Pinto, A, Trentin, L, Bocchia, M, Galimberti, Coviello, E, Mc, Morotti, A, Falini, B, Turrin, M, Tafuri, A, Billio, A, Gentile, M, Lemoli, M, 37, Venditti, A, Della Porta, M, Lanza, F, Rigacci, L, Tosi, P, Mohamed, S, Corso, A, Luppi, M, Giuliani, N, Busca, A, Pagano, L, Bruno, R, Grossi, P, Corradini, P, Passamonti, F, Arcaini, L, Zappasodi P, Cattaneo C, Ferretti V, Mina R, Ferreri AJ, Merli F, Oberti M, Krampera M, Romano A, Zerbi C, Ferrari J, Cavo M, Marco Salvini M, Bertù L, Fracchiolla N, Marchesi F, Massaia M, Marasco V, Cairoli R, Scattolin AM, Vannucchi AM, Gambacorti-Passerini C, Musto P, Gherlinzoni F, Cuneo A, Pinto A, Trentin L, Bocchia M, Coviello E, MC, Morotti A, Falini B, Turrin M, Tafuri A, Billio A, Gentile M, Lemoli M, Venditti A, Della Porta M, Lanza F, Rigacci L, Tosi P, Mohamed S, Corso A, Luppi M, Giuliani N, Busca A, Pagano L, Bruno R, Grossi P, Corradini P, Passamonti F, and Arcaini L.

Abstract

The impact of secondary infections (SI) on COVID-19 outcome in patients with hematological malignancies (HM) is scarcely documented. To evaluate incidence, clinical characteristics, and outcome of SI, we analyzed the microbiologically documented SI in a large multicenter cohort of adult HM patients with COVID-19. Among 1741 HM patients with COVID-19, 134 (7.7%) had 185 SI, with a 1-month cumulative incidence of 5%. Median time between COVID-19 diagnosis and SI was 16 days (IQR: 5–36). Acute myeloid leukemia (AML) and lymphoma/plasma cell neoplasms (PCN) were more frequent diagnoses in SI patients compared to patients without SI (AML: 14.9% vs. 7.1%; lymphoma/PCN 71.7% vs. 65.3%). Patients with SI were older (median age 70 vs. 66 years, p = 0.002), with more comorbidities (median Charlson Comorbidity Index 5 vs. 4, p < 0.001), higher frequency of critical COVID-19 (19.5% vs. 11.5%, p = 0.046), and more frequently not in complete remission (75% vs. 64.7% p = 0.024). Blood and bronchoalveolar lavage were the main sites of isolation for SI. Etiology of infections was bacterial in 80% (n = 148) of cases, mycotic in 9.7% (n = 18) and viral in 10.3% (n = 19); polymicrobial infections were observed in 24 patients (18%). Escherichia coli represented most of Gram-negative isolates (18.9%), while coagulase-negative Staphylococci were the most frequent among Gram-positive (14.2%). The 30-day mortality of patients with SI was higher when compared to patients without SI (69% vs. 15%, p < 0.001). The occurrence of SI worsened COVID-19 outcome in HM patients. Timely diagnosis and adequate management should be considered to improve their prognosis.

Published
2022

5. Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study

Author

Lanza, F, Monaco, F, Ciceri, F, Cairoli, R, Sacchi, M, Guidetti, A, Marchetti, M, Massaia, M, Arcaini, L, Krampera, M, Mohamed, S, Gherlinzoni, F, Mecucci, C, Gentile, M, Romano, I, Venditti, A, Ruggeri, M, Ferrero, D, Coviello, E, Fabbri, E, Corradini, P, Passamonti, F, Lanza F, Monaco F, Ciceri F, Cairoli R, Sacchi MV, Guidetti A, Marchetti M, Massaia M, Arcaini L, Krampera M, Mohamed S, Gherlinzoni F, Mecucci C, Gentile M, Romano I, Venditti A, Ruggeri M, Ferrero D, Coviello E, Fabbri E, Corradini P, Passamonti F., Lanza, F, Monaco, F, Ciceri, F, Cairoli, R, Sacchi, M, Guidetti, A, Marchetti, M, Massaia, M, Arcaini, L, Krampera, M, Mohamed, S, Gherlinzoni, F, Mecucci, C, Gentile, M, Romano, I, Venditti, A, Ruggeri, M, Ferrero, D, Coviello, E, Fabbri, E, Corradini, P, Passamonti, F, Lanza F, Monaco F, Ciceri F, Cairoli R, Sacchi MV, Guidetti A, Marchetti M, Massaia M, Arcaini L, Krampera M, Mohamed S, Gherlinzoni F, Mecucci C, Gentile M, Romano I, Venditti A, Ruggeri M, Ferrero D, Coviello E, Fabbri E, Corradini P, and Passamonti F.

Abstract

A multicenter retrospective study was designed to assess clinical outcome of COVID-19 in patients with hematological malignancies (HM) following treatment with anti-SARS-CoV-2 convalescent plasma (CP) or standard of care therapy. To this aim, a propensity score matching was used to assess the role of non-randomized administration of CP in this high-risk cohort of patients from the Italian Hematology Alliance on COVID-19 (ITA-HEMA-COV) project, now including 2049 untreated control patients. We investigated 30- and 90-day mortality, rate of admission to intensive care unit, proportion of patients requiring mechanical ventilatory support, hospitalization time, and SARS-CoV-2 clearance in 79 CP recipients and compared results with 158 propensity score-matched controls. Results indicated a lack of efficacy of CP in the study group compared with the untreated group, thus confirming the negative results obtained from randomized studies in immunocompetent individuals with COVID-19. In conclusion, this retrospective analysis did not meet the primary and secondary end points in any category of immunocompromized patients affected by HM.

Published
2022

6. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study

Author

Visco, C, Marcheselli, L, Mina, R, Sassone, M, Guidetti, A, Penna, D, Cattaneo, C, Bonuomo, V, Busca, A, Ferreri, A, Bruna, R, Petrucci, L, Cairoli, R, Salvini, M, Bertu, L, Ladetto, M, Pilerci, S, Pinto, A, Ramadan, S, Marchesi, F, Cavo, M, Arcaini, L, Coviello, E, Romano, A, Musto, P, Massaia, M, Fracchiolla, N, Marchetti, M, Scattolin, A, Tisi, M, Cuneo, A, Porta, M, Trentin, L, Turrini, M, Gherlinzoni, F, Tafuri, A, Galimberti, S, Bocchia, M, Cardinali, V, Cilloni, D, Corso, A, Armiento, D, Rigacci, L, La Barbera, E, Gambacorti Passerini, C, Visani, G, Vallisa, D, Venditti, A, Selleri, C, Conconi, A, Tosi, P, Lanza, F, Candoni, A, Krampera, M, Corradini, P, Passamonti, F, Merli, F, Visco C., Marcheselli L., Mina R., Sassone M., Guidetti A., Penna D., Cattaneo C., Bonuomo V., Busca A., Ferreri A. J. M., Bruna R., Petrucci L., Cairoli R., Salvini M., Bertu L., Ladetto M., Pilerci S., Pinto A., Ramadan S., Marchesi F., Cavo M., Arcaini L., Coviello E., Romano A., Musto P., Massaia M., Fracchiolla N., Marchetti M., Scattolin A., Tisi M. C., Cuneo A., Porta M. D., Trentin L., Turrini M., Gherlinzoni F., Tafuri A., Galimberti S., Bocchia M., Cardinali V., Cilloni D., Corso A., Armiento D., Rigacci L., La Barbera E. O., Gambacorti Passerini C., Visani G., Vallisa D., Venditti A., Selleri C., Conconi A., Tosi P., Lanza F., Candoni A., Krampera M., Corradini P., Passamonti F., Merli F., Visco, C, Marcheselli, L, Mina, R, Sassone, M, Guidetti, A, Penna, D, Cattaneo, C, Bonuomo, V, Busca, A, Ferreri, A, Bruna, R, Petrucci, L, Cairoli, R, Salvini, M, Bertu, L, Ladetto, M, Pilerci, S, Pinto, A, Ramadan, S, Marchesi, F, Cavo, M, Arcaini, L, Coviello, E, Romano, A, Musto, P, Massaia, M, Fracchiolla, N, Marchetti, M, Scattolin, A, Tisi, M, Cuneo, A, Porta, M, Trentin, L, Turrini, M, Gherlinzoni, F, Tafuri, A, Galimberti, S, Bocchia, M, Cardinali, V, Cilloni, D, Corso, A, Armiento, D, Rigacci, L, La Barbera, E, Gambacorti Passerini, C, Visani, G, Vallisa, D, Venditti, A, Selleri, C, Conconi, A, Tosi, P, Lanza, F, Candoni, A, Krampera, M, Corradini, P, Passamonti, F, Merli, F, Visco C., Marcheselli L., Mina R., Sassone M., Guidetti A., Penna D., Cattaneo C., Bonuomo V., Busca A., Ferreri A. J. M., Bruna R., Petrucci L., Cairoli R., Salvini M., Bertu L., Ladetto M., Pilerci S., Pinto A., Ramadan S., Marchesi F., Cavo M., Arcaini L., Coviello E., Romano A., Musto P., Massaia M., Fracchiolla N., Marchetti M., Scattolin A., Tisi M. C., Cuneo A., Porta M. D., Trentin L., Turrini M., Gherlinzoni F., Tafuri A., Galimberti S., Bocchia M., Cardinali V., Cilloni D., Corso A., Armiento D., Rigacci L., La Barbera E. O., Gambacorti Passerini C., Visani G., Vallisa D., Venditti A., Selleri C., Conconi A., Tosi P., Lanza F., Candoni A., Krampera M., Corradini P., Passamonti F., and Merli F.

Abstract

Lymphoma represents a heterogeneous hematological malignancy (HM), which is characterized by severe immunosuppression. Patients diagnosed of coronavirus disease 2019 (COVID-19) during the course of HM have been described to have poor outcome, with only few reports specifically addressing lymphoma patients. Here, we investigated the clinical behavior and clinical parameters of a large multicenter cohort of adult patients with different lymphoma subtypes, with the aim of identifying predictors of death. The study included 856 patients, of whom 619 were enrolled prospectively in a 1-year frame and were followed-up for a median of 66 days (range 1-395). Patients were managed as outpatient (not-admitted cohort, n 5 388) or required hospitalization (n 5 468), and median age was 63 years (range 19-94). Overall, the 30- and 100-days mortality was 13% (95% confidence interval (CI), 11% to 15%) and 23% (95% CI, 20% to 27%), respectively. Antilymphoma treatment, including anti-CD20 containing regimens, did not impact survival. Patients with Hodgkin’s lymphoma had the more favorable survival, but this was partly related to significantly younger age. The time interval between lymphoma diagnosis and COVID-19 was inversely related to mortality. Multivariable analysis recognized 4 easy-to-use factors (age, gender, lymphocyte, and platelet count) that were associated with risk of death, both in the admitted and in the not-admitted cohort (HR 3.79 and 8.85 for the intermediate- and high-risk group, respectively). Overall, our study shows that patients should not be deprived of the best available treatment of their underlying disease and indicates which patients are at higher risk of death. This study was registered with ClinicalTrials.gov, NCT04352556.

Published
2022

7. Late Mortality, Subsequent Malignant Neoplasms and Hospitalisations in Long-Term Survivors of Adolescent and Young Adult Hematological Cancers

Author

Trama, A., Vener, C., Lasalvia, P., Bernasconi, A., Zorzi, M., Andreano, A., Contiero, P., Manneschi, G., Falcini, F., Castaing, M., Filiberti, R. A., Gasparotti, C., Cirilli, C., Amodio, R., Bisceglia, I., Iacovacci, S., Vitale, M. F., Stracci, F., Gentilini, M. A., Tumino, R., Carone, S., Sampietro, G., Melcarne, A., Gatti, L., Boschetti, L., Corti, M., Rognoni, M., Coviello, E., Pesce, M. T., D'Orsi, G., Fanetti, A. C., De Lorenzis, L., Candela, G., Savoia, F., Pascucci, C., Castelli, M., Storchi, C., Trama, A, Vener, C, Lasalvia, P, Bernasconi, A, Zorzi, M, Andreano, A, Contiero, P, Manneschi, G, Falcini, F, Castaing, M, Filiberti, R, Gasparotti, C, Cirilli, C, Amodio, R, Bisceglia, I, Iacovacci, S, Vitale, M, Stracci, F, Gentilini, M, Tumino, R, Carone, S, Sampietro, G, Melcarne, A, Gatti, L, Boschetti, L, Corti, M, Rognoni, M, Coviello, E, Pesce, M, D'Orsi, G, Fanetti, A, De Lorenzis, L, Candela, G, Savoia, F, Pascucci, C, Castelli, M, and Storchi, C

Subjects
adolescents and young adults (AYAs), long-term outcome, Cancer Research, Oncology, cancer survivor, hematological cancers, cancer survivors, hematological cancer, population-based cohort, long-term outcomes
Abstract

BackgroundIncreased success in the treatment of hematological cancers contributed to the increase of 5-year survival for most adolescent and young adults (AYAs) with these tumours. However, as 5-year survival increased, it became clear that AYA long-term survivors were at increased risk for severe late effects. Moreover, limited information on long-term cancer impact is available for AYAs, since most studies focused on children and adolescents. We aimed to assess various long-term outcomes on AYA survivors of hematological cancers.MethodsWe selected patients diagnosed with a first primary hematological cancer between 1997 and 2006, in the Italian nationwide population-based cohort of AYA cancer survivors (i.e. alive at least 5 years after cancer diagnosis). Long-term outcomes of interest were: second malignant neoplasms (SMNs), hospitalizations and overall mortality. We calculated standardized incidence ratios (SIRs), standardized hospitalization rate ratios (SHRs) and standardized mortality rate ratios (SMRs). To study morbidity patterns over time, we modeled observed incidence rates by fitting flexible parametric models for nonlinear patterns and we used linear regression for linear patterns.ResultsThe study cohort included 5,042 AYA hematological cancer survivors of which 1,237 and 3,805 had a leukaemia and lymphoma diagnosis, respectively. AYA survivors were at substantially increased risk for SMN (SIR=2.1; 95%CI=1.7; 2.6), hospitalisation (SHR=1.5; 95%CI=1.5; 1.6), and mortality (SMR=1.4; 95%CI=1.2; 1.6) with differences between leukaemia and lymphoma survivors. The highest excess risks of hospitalisations were for infectious diseases, respiratory diseases, and diseases of blood and blood-forming organs. The morbidity pattern differs over time by morbidity type.ConclusionsOur results support the need for strict follow-up plans for survivors, and call for further study to better personalised follow-up plans for AYA cancer survivors.

Published
2022

8. Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV

Author

Zappasodi P, Cattaneo C, Ferretti V, Mina R, Ferreri AJ, Merli F, Oberti M, Krampera M, Romano A, Zerbi C, Ferrari J, Cavo M, Marco Salvini M, Bertù L, Fracchiolla N, Marchesi F, Massaia M, Marasco V, Cairoli R, Scattolin AM, Vannucchi AM, Gambacorti-Passerini C, Musto P, Gherlinzoni F, Cuneo A, Pinto A, Trentin L, Bocchia M, Galimberti, Coviello E, Morotti A, Falini B, Turrin M, Tafuri A, Billio A, Gentile M, Lemoli M, Venditti A, Della Porta M, Lanza F, Rigacci L, Tosi P, Mohamed S, Corso A, Luppi M, Giuliani N, Busca A, Pagano L, Bruno R, Grossi P, Corradini P, Passamonti F, Arcaini L., Zappasodi, P, Cattaneo, C, Ferretti, V, Mina, R, Ferreri, A, Merli, F, Oberti, M, Krampera, M, Romano, A, Zerbi, C, Ferrari, J, Cavo, M, Marco Salvini, M, Bertù, L, Fracchiolla, N, Marchesi, F, Massaia, M, Marasco, V, Cairoli, R, Scattolin, A, Vannucchi, A, Gambacorti-Passerini, C, Musto, P, Gherlinzoni, F, Cuneo, A, Pinto, A, Trentin, L, Bocchia, M, Galimberti, Coviello, E, Mc, Morotti, A, Falini, B, Turrin, M, Tafuri, A, Billio, A, Gentile, M, Lemoli, M, Venditti, A, Della Porta, M, Lanza, F, Rigacci, L, Tosi, P, Mohamed, S, Corso, A, Luppi, M, Giuliani, N, Busca, A, Pagano, L, Bruno, R, Grossi, P, Corradini, P, Passamonti, F, Arcaini, L, Zappasodi, Patrizia, Cattaneo, Chiara, Ferretti, Virginia Valeria, Mina, Roberto, Ferreri, Andrés José María, Merli, Francesco, Oberti, Margherita, Krampera, Mauro, Romano, Alessandra, Zerbi, Caterina, Ferrari, Jacqueline, Cavo, Michele, Salvini, Marco, Bertù, Lorenza, Fracchiolla, Nicola Stefano, Marchesi, Francesco, Massaia, Massimo, Marasco, Vincenzo, Cairoli, Roberto, Scattolin, Anna Maria, Vannucchi, Alessandro Maria, Gambacorti-Passerini, Carlo, Musto, Pellegrino, Gherlinzoni, Filippo, Cuneo, Antonio, Pinto, Antonello, Trentin, Livio, Bocchia, Monica, Galimberti, Sara, Coviello, Elisa, Tisi, Maria Chiara, Morotti, Alessandro, Falini, Brunangelo, Turrini, Mauro, Tafuri, Agostino, Billio, Atto, Gentile, Massimo, Lemoli, Roberto Massimo, Venditti, Adriano, Della Porta, Matteo Giovanni, Lanza, Francesco, Rigacci, Luigi, Tosi, Patrizia, Mohamed, Sara, Corso, Alessandro, Luppi, Mario, Giuliani, Nicola, Busca, Alessandro, Pagano, Livio, Bruno, Raffaele, Grossi, Paolo Antonio, Corradini, Paolo, Passamonti, Francesco, and Arcaini, Luca

Subjects
Cancer Research, Lymphoma, Coinfection, COVID-19, Hematology, General Medicine, Settore MED/15, hematological malignancie, secondary infections, Settore MED/15 - MALATTIE DEL SANGUE, COVID-19 Testing, Oncology, Hematologic Neoplasms, secondary infection, outcome, Humans, hematological malignancies, Aged
Abstract

The impact of secondary infections (SI) on COVID-19 outcome in patients with hematological malignancies (HM) is scarcely documented. To evaluate incidence, clinical characteristics, and outcome of SI, we analyzed the microbiologically documented SI in a large multicenter cohort of adult HM patients with COVID-19. Among 1741 HM patients with COVID-19, 134 (7.7%) had 185 SI, with a 1-month cumulative incidence of 5%. Median time between COVID-19 diagnosis and SI was 16 days (IQR: 5-36). Acute myeloid leukemia (AML) and lymphoma/plasma cell neoplasms (PCN) were more frequent diagnoses in SI patients compared to patients without SI (AML: 14.9% vs. 7.1%; lymphoma/PCN 71.7% vs. 65.3%). Patients with SI were older (median age 70 vs. 66 years, p = 0.002), with more comorbidities (median Charlson Comorbidity Index 5 vs. 4, p < 0.001), higher frequency of critical COVID-19 (19.5% vs. 11.5%, p = 0.046), and more frequently not in complete remission (75% vs. 64.7% p = 0.024). Blood and bronchoalveolar lavage were the main sites of isolation for SI. Etiology of infections was bacterial in 80% (n = 148) of cases, mycotic in 9.7% (n = 18) and viral in 10.3% (n = 19); polymicrobial infections were observed in 24 patients (18%). Escherichia coli represented most of Gram-negative isolates (18.9%), while coagulase-negative Staphylococci were the most frequent among Gram-positive (14.2%). The 30-day mortality of patients with SI was higher when compared to patients without SI (69% vs. 15%, p < 0.001). The occurrence of SI worsened COVID-19 outcome in HM patients. Timely diagnosis and adequate management should be considered to improve their prognosis.

Published
2022

9. COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies

Author

Passamonti, F, Romano, A, Salvini, M, Merli, F, Porta, M, Bruna, R, Coviello, E, Romano, I, Cairoli, R, Lemoli, R, Farina, F, Venditti, A, Busca, A, Ladetto, M, Massaia, M, Pinto, A, Arcaini, L, Tafuri, A, Marchesi, F, Fracchiolla, N, Bocchia, M, Armiento, D, Candoni, A, Krampera, M, Luppi, M, Cardinali, V, Galimberti, S, Cattaneo, C, La Barbera, E, Mina, R, Lanza, F, Visani, G, Musto, P, Petrucci, L, Zaja, F, Grossi, P, Bertu, L, Pagano, L, Corradini, P, Derenzini, E, Marchetti, M, Scattolin, A, Corso, A, Tosi, P, Gherlinzoni, F, Gambacorti Passerini, C, Cavo, M, Fava, C, Turrini, M, Visco, C, Zappasodi, P, Merli, M, Mora, B, Vannucchi, A, Passamonti F., Romano A., Salvini M., Merli F., Porta M. G. D., Bruna R., Coviello E., Romano I., Cairoli R., Lemoli R., Farina F., Venditti A., Busca A., Ladetto M., Massaia M., Pinto A., Arcaini L., Tafuri A., Marchesi F., Fracchiolla N., Bocchia M., Armiento D., Candoni A., Krampera M., Luppi M., Cardinali V., Galimberti S., Cattaneo C., La Barbera E. O., Mina R., Lanza F., Visani G., Musto P., Petrucci L., Zaja F., Grossi P. A., Bertu L., Pagano L., Corradini P., Derenzini E., Marchetti M., Scattolin A. M., Corso A., Tosi P., Gherlinzoni F., Gambacorti Passerini C., Cavo M., Fava C., Turrini M., Visco C., Zappasodi P., Merli M., Mora B., Vannucchi A. M., Passamonti, F, Romano, A, Salvini, M, Merli, F, Porta, M, Bruna, R, Coviello, E, Romano, I, Cairoli, R, Lemoli, R, Farina, F, Venditti, A, Busca, A, Ladetto, M, Massaia, M, Pinto, A, Arcaini, L, Tafuri, A, Marchesi, F, Fracchiolla, N, Bocchia, M, Armiento, D, Candoni, A, Krampera, M, Luppi, M, Cardinali, V, Galimberti, S, Cattaneo, C, La Barbera, E, Mina, R, Lanza, F, Visani, G, Musto, P, Petrucci, L, Zaja, F, Grossi, P, Bertu, L, Pagano, L, Corradini, P, Derenzini, E, Marchetti, M, Scattolin, A, Corso, A, Tosi, P, Gherlinzoni, F, Gambacorti Passerini, C, Cavo, M, Fava, C, Turrini, M, Visco, C, Zappasodi, P, Merli, M, Mora, B, Vannucchi, A, Passamonti F., Romano A., Salvini M., Merli F., Porta M. G. D., Bruna R., Coviello E., Romano I., Cairoli R., Lemoli R., Farina F., Venditti A., Busca A., Ladetto M., Massaia M., Pinto A., Arcaini L., Tafuri A., Marchesi F., Fracchiolla N., Bocchia M., Armiento D., Candoni A., Krampera M., Luppi M., Cardinali V., Galimberti S., Cattaneo C., La Barbera E. O., Mina R., Lanza F., Visani G., Musto P., Petrucci L., Zaja F., Grossi P. A., Bertu L., Pagano L., Corradini P., Derenzini E., Marchetti M., Scattolin A. M., Corso A., Tosi P., Gherlinzoni F., Gambacorti Passerini C., Cavo M., Fava C., Turrini M., Visco C., Zappasodi P., Merli M., Mora B., and Vannucchi A. M.

Abstract

COVID-19 is associated with high mortality in patients with haematological malignancies (HM) and rate of seroconversion is unknown. The ITA-HEMA-COV project (NCT04352556) investigated patterns of seroconversion for SARS-CoV-2 IgG in patients with HMs. A total of 237 patients, SARS-CoV-2 PCR-positive with at least one SARS-CoV-2 IgG test performed during their care, entered the analysis. Among these, 62 (26·2%) had myeloid, 121 (51·1%) lymphoid and 54 (22·8%) plasma cell neoplasms. Overall, 69% of patients (164 of 237) had detectable IgG SARS-CoV-2 serum antibodies. Serologically negative patients (31%, 73 of 237) were evenly distributed across patients with myeloid, lymphoid and plasma cell neoplasms. In the multivariable logistic regression, chemoimmunotherapy [odds ratio (OR), 3·42; 95% confidence interval (CI), 1·04–11·21; P = 0·04] was associated with a lower rate of seroconversion. This effect did not decline after 180 days from treatment withdrawal (OR, 0·35; 95% CI: 0·11–1·13; P = 0·08). This study demonstrates a low rate of seroconversion in HM patients and indicates that treatment-mediated immune dysfunction is the main driver. As a consequence, we expect a low rate of seroconversion after vaccination and thus we suggest testing the efficacy of seroconversion in HM patients.

Published
2021

10. Dirofilariosis infestation of pectoralis major muscle in Italy, a case report.

Author

Napolitano, A. G., Pallotto, C., Pourmolkara, D., Vinci, D., and Coviello, E.

Subjects
ZOONOSES, PECTORALIS muscle, INFLAMMATION, SUBCUTANEOUS infusions
Abstract

Zoonotic dirofilariasis infestation, caused by Dirofilaria Repens, is described worldwide in different countries. A 31-years-old male patient presented thoracic muscle pain after growth of an ovoidal undefine cyst in left parasternal region. Patient reported several contacts with different species of animals for a familiar activity. In absence of blood inflammatory indices and systemic symptoms, imaging studies showed a suspected muscle cyst infection. Surgical excision was performed and microbiology confirmed parasite nature. Dirofilaria Repens, probably adult female, was identified. Treatment resulted to be definitive and any other clinical and surgical approach was needed. Healing time was uneventful and follow-up showed no further systemic relapses. The case highlights the effectiveness of surgical treatment in this subcutaneous infestation for an increasing number of human cases reported in endemic areas such as Central Italy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

11. Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV

Author

Zappasodi, P., Cattaneo, C., Valeria Ferretti, V., Mina, R., Jose Maria Ferreri, A., Merli, F., Oberti, M., Krampera, M., Romano, A., Zerbi, C., Ferrari, J., Cavo, M., Salvini, M., Bertu, L., Stefano Fracchiolla, N., Marchesi, F., Massaia, M., Marasco, V., Cairoli, R., Maria Scattolin, A., Maria Vannucchi, A., Gambacorti-Passerini, C., Musto, P., Gherlinzoni, F., Cuneo, A., Pinto, A., Trentin, L., Bocchia, M., Galimberti, S., Coviello, E., Chiara Tisi, M., Morotti, A., Falini, B., Turrini, M., Tafuri, A., Billio, A., Gentile, M., Massimo Lemoli, R., Venditti, A., Giovanni Della Porta, M., Lanza, F., Rigacci, L., Tosi, P., Mohamed, S., Corso, A., Luppi, M., Giuliani, N., Busca, A., Pagano, Livio, Bruno, R., Antonio Grossi, P., Corradini, P., Passamonti, F., Arcaini, L., Pagano L. (ORCID:0000-0001-8287-928X), Zappasodi, P., Cattaneo, C., Valeria Ferretti, V., Mina, R., Jose Maria Ferreri, A., Merli, F., Oberti, M., Krampera, M., Romano, A., Zerbi, C., Ferrari, J., Cavo, M., Salvini, M., Bertu, L., Stefano Fracchiolla, N., Marchesi, F., Massaia, M., Marasco, V., Cairoli, R., Maria Scattolin, A., Maria Vannucchi, A., Gambacorti-Passerini, C., Musto, P., Gherlinzoni, F., Cuneo, A., Pinto, A., Trentin, L., Bocchia, M., Galimberti, S., Coviello, E., Chiara Tisi, M., Morotti, A., Falini, B., Turrini, M., Tafuri, A., Billio, A., Gentile, M., Massimo Lemoli, R., Venditti, A., Giovanni Della Porta, M., Lanza, F., Rigacci, L., Tosi, P., Mohamed, S., Corso, A., Luppi, M., Giuliani, N., Busca, A., Pagano, Livio, Bruno, R., Antonio Grossi, P., Corradini, P., Passamonti, F., Arcaini, L., and Pagano L. (ORCID:0000-0001-8287-928X)

Abstract

The impact of secondary infections (SI) on COVID-19 outcome in patients with hematological malignancies (HM) is scarcely documented. To evaluate incidence, clinical characteristics, and outcome of SI, we analyzed the microbiologically documented SI in a large multicenter cohort of adult HM patients with COVID-19. Among 1741 HM patients with COVID-19, 134 (7.7%) had 185 SI, with a 1-month cumulative incidence of 5%. Median time between COVID-19 diagnosis and SI was 16 days (IQR: 5–36). Acute myeloid leukemia (AML) and lymphoma/plasma cell neoplasms (PCN) were more frequent diagnoses in SI patients compared to patients without SI (AML: 14.9% vs. 7.1%; lymphoma/PCN 71.7% vs. 65.3%). Patients with SI were older (median age 70 vs. 66 years, p = 0.002), with more comorbidities (median Charlson Comorbidity Index 5 vs. 4, p < 0.001), higher frequency of critical COVID-19 (19.5% vs. 11.5%, p = 0.046), and more frequently not in complete remission (75% vs. 64.7% p = 0.024). Blood and bronchoalveolar lavage were the main sites of isolation for SI. Etiology of infections was bacterial in 80% (n = 148) of cases, mycotic in 9.7% (n = 18) and viral in 10.3% (n = 19); polymicrobial infections were observed in 24 patients (18%). Escherichia coli represented most of Gram-negative isolates (18.9%), while coagulase-negative Staphylococci were the most frequent among Gram-positive (14.2%). The 30-day mortality of patients with SI was higher when compared to patients without SI (69% vs. 15%, p < 0.001). The occurrence of SI worsened COVID-19 outcome in HM patients. Timely diagnosis and adequate management should be considered to improve their prognosis.

Published
2022

12. Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID-19: The GIMEMA EMATO-0321 study

Author

Marasco, V., Piciocchi, A., Candoni, A., Pagano, Livio, Guidetti, A., Musto, P., Bruna, R., Bocchia, M., Visentin, A., Turrini, M., Tucci, A., Pilerci, S., Fianchi, Luana, Salvini, M., Galimberti, S., Coviello, E., Selleri, C., Luppi, M., Crea, E., Fazi, P., Passamonti, F., Corradini, P., Pagano L. (ORCID:0000-0001-8287-928X), Fianchi L., Marasco, V., Piciocchi, A., Candoni, A., Pagano, Livio, Guidetti, A., Musto, P., Bruna, R., Bocchia, M., Visentin, A., Turrini, M., Tucci, A., Pilerci, S., Fianchi, Luana, Salvini, M., Galimberti, S., Coviello, E., Selleri, C., Luppi, M., Crea, E., Fazi, P., Passamonti, F., Corradini, P., Pagano L. (ORCID:0000-0001-8287-928X), and Fianchi L.

Abstract

COVID-19 continues to be a relevant issue among patients with haematological malignancies (HM). Vaccines are frequently not effective in subjects on active treatment. In this multicentre retrospective study of Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), we collected data from 91 paucisymptomatic HM patients treated with anti-spike neutralizing monoclonal antibodies (nMoAbs) to determine time to viral clearance, referencing it to the expected value of 28 days from an historical group of untreated paucisymptomatic patients. Secondary endpoints included rate of hospitalization, intensive care unit (ICU) admission, COVID-19 related death and safety. SARS-CoV-2 molecular swab negativity was obtained in 86 patients (95%), with a median time of 18 days (IQR 13–26; p < 0.0001). We did not find significant variations according to age, diagnosis, treatment type, vaccination status or nMoAbs type. Rate of hospitalization due to COVID-19 progression was 12% (11/91), with 2 patients (2.2%) requiring ICU admission. With a median follow-up of 2.33 months, the overall mortality was 5.5% (5/91), with 3 deaths due to COVID-19. Side effects were rare and self-limiting. Our data suggest that nMoAbs can limit the detrimental effect of immunosuppressive treatments on COVID-19 clinical progression and time to viral clearance. The original trial was registered at www.clinicaltrials.gov as #NCT04932967.

Published
2022

13. COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies

Author

Passamonti, F., Romano, A., Salvini, M., Merli, F., Porta, M. G. D., Bruna, R., Coviello, E., Romano, I., Cairoli, R., Lemoli, R., Farina, F., Venditti, A., Busca, A., Ladetto, M., Massaia, M., Pinto, A., Arcaini, L., Tafuri, A., Marchesi, F., Fracchiolla, N., Bocchia, M., Armiento, D., Candoni, A., Krampera, M., Luppi, M., Cardinali, V., Galimberti, S., Cattaneo, C., La Barbera, E. O., Mina, R., Lanza, F., Visani, G., Musto, P., Petrucci, L., Zaja, F., Grossi, P. A., Bertu, L., Pagano, Livio, Corradini, P., Derenzini, E., Marchetti, M., Scattolin, A. M., Corso, A., Tosi, P., Gherlinzoni, F., Passerini, C. G., Cavo, M., Fava, C., Turrini, M., Visco, C., Zappasodi, P., Merli, M., Mora, B., Vannucchi, A. M., Pagano L. (ORCID:0000-0001-8287-928X), Passamonti, F., Romano, A., Salvini, M., Merli, F., Porta, M. G. D., Bruna, R., Coviello, E., Romano, I., Cairoli, R., Lemoli, R., Farina, F., Venditti, A., Busca, A., Ladetto, M., Massaia, M., Pinto, A., Arcaini, L., Tafuri, A., Marchesi, F., Fracchiolla, N., Bocchia, M., Armiento, D., Candoni, A., Krampera, M., Luppi, M., Cardinali, V., Galimberti, S., Cattaneo, C., La Barbera, E. O., Mina, R., Lanza, F., Visani, G., Musto, P., Petrucci, L., Zaja, F., Grossi, P. A., Bertu, L., Pagano, Livio, Corradini, P., Derenzini, E., Marchetti, M., Scattolin, A. M., Corso, A., Tosi, P., Gherlinzoni, F., Passerini, C. G., Cavo, M., Fava, C., Turrini, M., Visco, C., Zappasodi, P., Merli, M., Mora, B., Vannucchi, A. M., and Pagano L. (ORCID:0000-0001-8287-928X)

Abstract

COVID-19 is associated with high mortality in patients with haematological malignancies (HM) and rate of seroconversion is unknown. The ITA-HEMA-COV project (NCT04352556) investigated patterns of seroconversion for SARS-CoV-2 IgG in patients with HMs. A total of 237 patients, SARS-CoV-2 PCR-positive with at least one SARS-CoV-2 IgG test performed during their care, entered the analysis. Among these, 62 (26·2%) had myeloid, 121 (51·1%) lymphoid and 54 (22·8%) plasma cell neoplasms. Overall, 69% of patients (164 of 237) had detectable IgG SARS-CoV-2 serum antibodies. Serologically negative patients (31%, 73 of 237) were evenly distributed across patients with myeloid, lymphoid and plasma cell neoplasms. In the multivariable logistic regression, chemoimmunotherapy [odds ratio (OR), 3·42; 95% confidence interval (CI), 1·04–11·21; P = 0·04] was associated with a lower rate of seroconversion. This effect did not decline after 180 days from treatment withdrawal (OR, 0·35; 95% CI: 0·11–1·13; P = 0·08). This study demonstrates a low rate of seroconversion in HM patients and indicates that treatment-mediated immune dysfunction is the main driver. As a consequence, we expect a low rate of seroconversion after vaccination and thus we suggest testing the efficacy of seroconversion in HM patients.

Published
2021

14. PS1535 AUTOLOGOUS STEM CELL TRANSPLANT FOLLOWED BY POST-TRANSPLANT IMMUNOTHERAPY WITH NIVOLUMAB AND UNSELECTED AUTOLOGOUS LYMPHOCYTES INFUSION AS SALVAGE THERAPY FOR RELAPSED/REFRACTORY HODGKIN LYMPHOMA

Author

Guolo, F., primary, Minetto, P., additional, Ballerini, F., additional, Canale, F.A., additional, Frello, M., additional, Coviello, E., additional, Manconi, L., additional, Kunkl, A., additional, Tedone, E., additional, Contini, P., additional, Mangerini, R., additional, Fenoglio, D., additional, Bo, A., additional, Luigi, M.C. De, additional, Ruzzenenti, M.R., additional, Carlier, P., additional, Serio, A., additional, Lucchetti, S., additional, Strada, P., additional, Gobbi, M., additional, Ravetti, J.L., additional, Marcenaro, E., additional, and Lemoli, R.M., additional

Published
2019
Full Text
View/download PDF

15. Cancer incidence and mortality trends from 2003 to 2014 in Italy

Author

Buzzoni, Carlotta, primary, Crocetti, Emanuele, additional, Guzzinati, Stefano, additional, Dal Maso, Luigino, additional, Francisci, Silvia, additional, Mazzoleni, G, additional, Ferrara, MA, additional, Caputo, E, additional, Coviello, E, additional, Galasso, R, additional, Citarella, A, additional, Sampietro, G, additional, Magoni, M, additional, Ardizzone, A, additional, D’Argenzio, A, additional, Sutera Sardo, A, additional, Giorno, A, additional, La Greca, G, additional, Ricci, P, additional, Ferretti, S, additional, Palma, F, additional, Serraino, D, additional, Iacovacci, S, additional, Melcarne, A, additional, Puppo, A, additional, Sciacca, S, additional, Russo, AG, additional, Caruso, Bianca, additional, Cavalieri d’Oro, L, additional, D’Orsi, G, additional, Fusco, M, additional, Usala, M, additional, Vitale, F, additional, Cusimano, R, additional, Michiara, M, additional, Boschetti, L, additional, Chiaranda, G, additional, Rosso, S, additional, Tumino, R, additional, Mangone, L, additional, Valenti Clemente, S, additional, Falcini, F, additional, Caiazzo, AL, additional, Cesaraccio, R, additional, Tisano, F, additional, Fanetti, AC, additional, Minerba, S, additional, Caldarella, A, additional, Candela, G, additional, Piffer, S, additional, Cania, A, additional, Castelli, M, additional, Pisani, M, additional, Tagliabue, G, additional, Bovo, E, additional, and Brustolin, A, additional

Published
2019
Full Text
View/download PDF

16. Trends of colorectal cancer incidence and mortality rates from 2003 to 2014 in Italy

Author

Zorzi, Manuel, primary, Dal Maso, Luigino, additional, Francisci, Silvia, additional, Buzzoni, Carlotta, additional, Rugge, Massimo, additional, Guzzinati, Stefano, additional, Mazzoleni, G., additional, Coviello, E., additional, Galasso, R., additional, Sampietro, G., additional, Magoni, M., additional, Ardizzone, A., additional, D‘Argenzio, A., additional, Sutera Sardo, A., additional, Giorno, A., additional, La Greca, G., additional, Ricci, P., additional, Ferretti, S., additional, Palma, F., additional, Serraino, D., additional, Iacovacci, S., additional, Melcarne, A., additional, Puppo, A., additional, Sciacca, S., additional, Russo, A.G., additional, Caruso, B., additional, Cavalieri d’Oro, L., additional, D‘Orsi, G., additional, Fusco, M., additional, Usala, M., additional, Vitale, F., additional, Cusimano, R., additional, Michiara, M., additional, Boschetti, L., additional, Chiaranda, G., additional, Rosso, S., additional, Tumino, R., additional, Mangone, L., additional, Falcini, F., additional, Caiazzo, A.L., additional, Cesaraccio, R., additional, Tisano, F., additional, Fanetti, A.C., additional, Minerba, S., additional, Caldarella, A., additional, Candela, G., additional, Piffer, S., additional, Cania, A., additional, Castelli, M., additional, Pisani, M., additional, Tagliabue, G., additional, Bovo, E., additional, and Brustolin, A., additional

Published
2019
Full Text
View/download PDF

17. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries

Author

Allemani, Claudia, primary, Matsuda, Tomohiro, additional, Di Carlo, Veronica, additional, Harewood, Rhea, additional, Matz, Melissa, additional, Nikšić, Maja, additional, Bonaventure, Audrey, additional, Valkov, Mikhail, additional, Johnson, Christopher J, additional, Estève, Jacques, additional, Ogunbiyi, Olufemi J, additional, Azevedo e Silva, Gulnar, additional, Chen, Wan-Qing, additional, Eser, Sultan, additional, Engholm, Gerda, additional, Stiller, Charles A, additional, Monnereau, Alain, additional, Woods, Ryan R, additional, Visser, Otto, additional, Lim, Gek Hsiang, additional, Aitken, Joanne, additional, Weir, Hannah K, additional, Coleman, Michel P, additional, Bouzbid, S, additional, Hamdi-Chérif, M, additional, Zaidi, Z, additional, Meguenni, K, additional, Regagba, D, additional, Bayo, S, additional, Cheick Bougadari, T, additional, Manraj, S S, additional, Bendahhou, K, additional, Fabowale, A, additional, Bradshaw, D, additional, Somdyala, N I M, additional, Kumcher, I, additional, Moreno, F, additional, Calabrano, G H, additional, Espinola, S B, additional, Carballo Quintero, B, additional, Fita, R, additional, Diumenjo, M C, additional, Laspada, W D, additional, Ibañez, S G, additional, Lima, C A, additional, De Souza, P C F, additional, Del Pino, K, additional, Laporte, C, additional, Curado, M P, additional, de Oliveira, J C, additional, Veneziano, C L A, additional, Veneziano, D B, additional, Latorre, M R D O, additional, Tanaka, L F, additional, Rebelo, M S, additional, Santos, M O, additional, Galaz, J C, additional, Aparicio Aravena, M, additional, Sanhueza Monsalve, J, additional, Herrmann, D A, additional, Vargas, S, additional, Herrera, V M, additional, Uribe, C J, additional, Bravo, L E, additional, Garcia, L S, additional, Arias-Ortiz, N E, additional, Morantes, D, additional, Jurado, D M, additional, Yépez Chamorro, M C, additional, Delgado, S, additional, Ramirez, M, additional, Galán Alvarez, Y H, additional, Torres, P, additional, Martínez-Reyes, F, additional, Jaramillo, L, additional, Quinto, R, additional, Castillo, J, additional, Mendoza, M, additional, Cueva, P, additional, Yépez, J G, additional, Bhakkan, B, additional, Deloumeaux, J, additional, Joachim, C, additional, Macni, J, additional, Carrillo, R, additional, Shalkow Klincovstein, J, additional, Rivera Gomez, R, additional, Poquioma, E, additional, Tortolero-Luna, G, additional, Zavala, D, additional, Alonso, R, additional, Barrios, E, additional, Eckstrand, A, additional, Nikiforuk, C, additional, Noonan, G, additional, Turner, D, additional, Kumar, E, additional, Zhang, B, additional, McCrate, F R, additional, Ryan, S, additional, MacIntyre, M, additional, Saint-Jacques, N, additional, Nishri, D E, additional, McClure, C A, additional, Vriends, K A, additional, Kozie, S, additional, Stuart-Panko, H, additional, Freeman, T, additional, George, J T, additional, Brockhouse, J T, additional, O'Brien, D K, additional, Holt, A, additional, Almon, L, additional, Kwong, S, additional, Morris, C, additional, Rycroft, R, additional, Mueller, L, additional, Phillips, C E, additional, Brown, H, additional, Cromartie, B, additional, Schwartz, A G, additional, Vigneau, F, additional, Levin, G M, additional, Wohler, B, additional, Bayakly, R, additional, Ward, K C, additional, Gomez, S L, additional, McKinley, M, additional, Cress, R, additional, Green, M D, additional, Miyagi, K, additional, Ruppert, L P, additional, Lynch, C F, additional, Huang, B, additional, Tucker, T C, additional, Deapen, D, additional, Liu, L, additional, Hsieh, M C, additional, Wu, X C, additional, Schwenn, M, additional, Gershman, S T, additional, Knowlton, R C, additional, Alverson, G, additional, Copeland, G E, additional, Bushhouse, S, additional, Rogers, D B, additional, Jackson-Thompson, J, additional, Lemons, D, additional, Zimmerman, H J, additional, Hood, M, additional, Roberts-Johnson, J, additional, Rees, J R, additional, Riddle, B, additional, Pawlish, K S, additional, Stroup, A, additional, Key, C, additional, Wiggins, C, additional, Kahn, A R, additional, Schymura, M J, additional, Radhakrishnan, S, additional, Rao, C, additional, Giljahn, L K, additional, Slocumb, R M, additional, Espinoza, R E, additional, Khan, F, additional, Aird, K G, additional, Beran, T, additional, Rubertone, J J, additional, Slack, S J, additional, Garcia, L, additional, Rousseau, D L, additional, Janes, T A, additional, Schwartz, S M, additional, Bolick, S W, additional, Hurley, D M, additional, Whiteside, M A, additional, Miller-Gianturco, P, additional, Williams, M A, additional, Herget, K, additional, Sweeney, C, additional, Johnson, A T, additional, Keitheri Cheteri, M B, additional, Migliore Santiago, P, additional, Blankenship, S E, additional, Farley, S, additional, Borchers, R, additional, Malicki, R, additional, Espinoza, J R, additional, Grandpre, J, additional, Wilson, R, additional, Edwards, B K, additional, Mariotto, A, additional, Lei, Y, additional, Wang, N, additional, Chen, J S, additional, Zhou, Y, additional, He, Y T, additional, Song, G H, additional, Gu, X P, additional, Mei, D, additional, Mu, H J, additional, Ge, H M, additional, Wu, T H, additional, Li, Y Y, additional, Zhao, D L, additional, Jin, F, additional, Zhang, J H, additional, Zhu, F D, additional, Junhua, Q, additional, Yang, Y L, additional, Jiang, C X, additional, Biao, W, additional, Wang, J, additional, Li, Q L, additional, Yi, H, additional, Zhou, X, additional, Dong, J, additional, Li, W, additional, Fu, F X, additional, Liu, S Z, additional, Chen, J G, additional, Zhu, J, additional, Li, Y H, additional, Lu, Y Q, additional, Fan, M, additional, Huang, S Q, additional, Guo, G P, additional, Zhaolai, H, additional, Wei, K, additional, Zeng, H, additional, Demetriou, A V, additional, Mang, W K, additional, Ngan, K C, additional, Kataki, A C, additional, Krishnatreya, M, additional, Jayalekshmi, P A, additional, Sebastian, P, additional, Nandakumar, A, additional, Malekzadeh, R, additional, Roshandel, G, additional, Keinan-Boker, L, additional, Silverman, B G, additional, Ito, H, additional, Nakagawa, H, additional, Sato, M, additional, Tobori, F, additional, Nakata, I, additional, Teramoto, N, additional, Hattori, M, additional, Kaizaki, Y, additional, Moki, F, additional, Sugiyama, H, additional, Utada, M, additional, Nishimura, M, additional, Yoshida, K, additional, Kurosawa, K, additional, Nemoto, Y, additional, Narimatsu, H, additional, Sakaguchi, M, additional, Kanemura, S, additional, Naito, M, additional, Narisawa, R, additional, Miyashiro, I, additional, Nakata, K, additional, Sato, S, additional, Yoshii, M, additional, Oki, I, additional, Fukushima, N, additional, Shibata, A, additional, Iwasa, K, additional, Ono, C, additional, Nimri, O, additional, Jung, K W, additional, Won, Y J, additional, Alawadhi, E, additional, Elbasmi, A, additional, Ab Manan, A, additional, Adam, F, additional, Sanjaajmats, E, additional, Tudev, U, additional, Ochir, C, additional, Al Khater, A M, additional, El Mistiri, M M, additional, Teo, Y Y, additional, Chiang, C J, additional, Lee, W C, additional, Buasom, R, additional, Sangrajrang, S, additional, Kamsa-ard, S, additional, Wiangnon, S, additional, Daoprasert, K, additional, Pongnikorn, D, additional, Leklob, A, additional, Sangkitipaiboon, S, additional, Geater, S L, additional, Sriplung, H, additional, Ceylan, O, additional, Kög, I, additional, Dirican, O, additional, Köse, T, additional, Gurbuz, T, additional, Karaşahin, F E, additional, Turhan, D, additional, Aktaş, U, additional, Halat, Y, additional, Yakut, C I, additional, Altinisik, M, additional, Cavusoglu, Y, additional, Türkköylü, A, additional, Üçüncü, N, additional, Hackl, M, additional, Zborovskaya, A A, additional, Aleinikova, O V, additional, Henau, K, additional, Van Eycken, L, additional, Valerianova, Z, additional, Yordanova, M R, additional, Šekerija, M, additional, Dušek, L, additional, Zvolský, M, additional, Storm, H, additional, Innos, K, additional, Mägi, M, additional, Malila, N, additional, Seppä, K, additional, Jégu, J, additional, Velten, M, additional, Cornet, E, additional, Troussard, X, additional, Bouvier, A M, additional, Guizard, A V, additional, Bouvier, V, additional, Launoy, G, additional, Arveux, P, additional, Maynadié, M, additional, Mounier, M, additional, Woronoff, A S, additional, Daoulas, M, additional, Robaszkiewicz, M, additional, Clavel, J, additional, Goujon, S, additional, Lacour, B, additional, Baldi, I, additional, Pouchieu, C, additional, Amadeo, B, additional, Coureau, G, additional, Orazio, S, additional, Preux, P M, additional, Rharbaoui, F, additional, Marrer, E, additional, Trétarre, B, additional, Colonna, M, additional, Delafosse, P, additional, Ligier, K, additional, Plouvier, S, additional, Cowppli-Bony, A, additional, Molinié, F, additional, Bara, S, additional, Ganry, O, additional, Lapôtre-Ledoux, B, additional, Grosclaude, P, additional, Bossard, N, additional, Uhry, Z, additional, Bray, F, additional, Piñeros, M, additional, Stabenow, R, additional, Wilsdorf-Köhler, H, additional, Eberle, A, additional, Luttmann, S, additional, Löhden, I, additional, Nennecke, A L, additional, Kieschke, J, additional, Sirri, E, additional, Emrich, K, additional, Zeissig, S R, additional, Holleczek, B, additional, Eisemann, N, additional, Katalinic, A, additional, Asquez, R A, additional, Kumar, V, additional, Petridou, E, additional, Ólafsdóttir, E J, additional, Tryggvadóttir, L, additional, Clough-Gorr, K, additional, Walsh, P M, additional, Sundseth, H, additional, Mazzoleni, G, additional, Vittadello, F, additional, Coviello, E, additional, Cuccaro, F, additional, Galasso, R, additional, Sampietro, G, additional, Giacomin, A, additional, Magoni, M, additional, Ardizzone, A, additional, D'Argenzio, A, additional, Castaing, M, additional, Grosso, G, additional, Lavecchia, A M, additional, Sutera Sardo, A, additional, Gola, G, additional, Gatti, L, additional, Ricci, P, additional, Ferretti, S, additional, Serraino, D, additional, Zucchetto, A, additional, Celesia, M V, additional, Filiberti, R A, additional, Pannozzo, F, additional, Melcarne, A, additional, Quarta, F, additional, Russo, A G, additional, Carrozzi, G, additional, Cirilli, C, additional, Cavalieri d'Oro, L, additional, Rognoni, M, additional, Fusco, M, additional, Vitale, M F, additional, Usala, M, additional, Cusimano, R, additional, Mazzucco, W, additional, Michiara, M, additional, Sgargi, P, additional, Boschetti, L, additional, Borciani, E, additional, Seghini, P, additional, Maule, M M, additional, Merletti, F, additional, Tumino, R, additional, Mancuso, P, additional, Vicentini, M, additional, Cassetti, T, additional, Sassatelli, R, additional, Falcini, F, additional, Giorgetti, S, additional, Caiazzo, A L, additional, Cavallo, R, additional, Cesaraccio, R, additional, Pirino, D R, additional, Contrino, M L, additional, Tisano, F, additional, Fanetti, A C, additional, Maspero, S, additional, Carone, S, additional, Mincuzzi, A, additional, Candela, G, additional, Scuderi, T, additional, Gentilini, M A, additional, Piffer, S, additional, Rosso, S, additional, Barchielli, A, additional, Caldarella, A, additional, Bianconi, F, additional, Stracci, F, additional, Contiero, P, additional, Tagliabue, G, additional, Rugge, M, additional, Zorzi, M, additional, Beggiato, S, additional, Brustolin, A, additional, Berrino, F, additional, Gatta, G, additional, Sant, M, additional, Buzzoni, C, additional, Mangone, L, additional, Capocaccia, R, additional, De Angelis, R, additional, Zanetti, R, additional, Maurina, A, additional, Pildava, S, additional, Lipunova, N, additional, Vincerževskiené, I, additional, Agius, D, additional, Calleja, N, additional, Siesling, S, additional, Larønningen, S, additional, Møller, B, additional, Dyzmann-Sroka, A, additional, Trojanowski, M, additional, Góźdź, S, additional, Mężyk, R, additional, Mierzwa, T, additional, Molong, L, additional, Rachtan, J, additional, Szewczyk, S, additional, Błaszczyk, J, additional, Kępska, K, additional, Kościańska, B, additional, Tarocińska, K, additional, Zwierko, M, additional, Drosik, K, additional, Maksimowicz, K M, additional, Purwin-Porowska, E, additional, Reca, E, additional, Wójcik-Tomaszewska, J, additional, Tukiendorf, A, additional, Grądalska-Lampart, M, additional, Radziszewska, A U, additional, Gos, A, additional, Talerczyk, M, additional, Wyborska, M, additional, Didkowska, J A, additional, Wojciechowska, U, additional, Bielska-Lasota, M, additional, Forjaz de Lacerda, G, additional, Rego, R A, additional, Bastos, J, additional, Silva, M A, additional, Antunes, L, additional, Laranja Pontes, J, additional, Mayer-da-Silva, A, additional, Miranda, A, additional, Blaga, L M, additional, Coza, D, additional, Gusenkova, L, additional, Lazarevich, O, additional, Prudnikova, O, additional, Vjushkov, D M, additional, Egorova, A G, additional, Orlov, A E, additional, Kudyakov, L A, additional, Pikalova, L V, additional, Adamcik, J, additional, Safaei Diba, C, additional, Primic-Žakelj, M, additional, Zadnik, V, additional, Larrañaga, N, additional, Lopez de Munain, A, additional, Herrera, A A, additional, Redondas, R, additional, Marcos-Gragera, R, additional, Vilardell Gil, M L, additional, Molina, E, additional, Sánchez Perez, M J, additional, Franch Sureda, P, additional, Ramos Montserrat, M, additional, Chirlaque, M D, additional, Navarro, C, additional, Ardanaz, E E, additional, Guevara, M M, additional, Fernández-Delgado, R, additional, Peris-Bonet, R, additional, Carulla, M, additional, Galceran, J, additional, Alberich, C, additional, Vicente-Raneda, M, additional, Khan, S, additional, Pettersson, D, additional, Dickman, P, additional, Avelina, I, additional, Staehelin, K, additional, Camey, B, additional, Bouchardy, C, additional, Schaffar, R, additional, Frick, H, additional, Herrmann, C, additional, Bulliard, J L, additional, Maspoli-Conconi, M, additional, Kuehni, C E, additional, Redmond, S M, additional, Bordoni, A, additional, Ortelli, L, additional, Chiolero, A, additional, Konzelmann, I, additional, Matthes, K L, additional, Rohrmann, S, additional, Broggio, J, additional, Rashbass, J, additional, Fitzpatrick, D, additional, Gavin, A, additional, Clark, D I, additional, Deas, A J, additional, Huws, D W, additional, White, C, additional, Montel, L, additional, Rachet, B, additional, Turculet, A D, additional, Stephens, R, additional, Chalker, E, additional, Phung, H, additional, Walton, R, additional, You, H, additional, Guthridge, S, additional, Johnson, F, additional, Gordon, P, additional, D'Onise, K, additional, Priest, K, additional, Stokes, B C, additional, Venn, A, additional, Farrugia, H, additional, Thursfield, V, additional, Dowling, J, additional, Currow, D, additional, Hendrix, J, additional, and Lewis, C, additional

Published
2018
Full Text
View/download PDF

18. LE SCELTE DI RISK MANAGEMENT NELLA GESTIONE DELLE CATASTROFI NATURALI

Author

Antonio Coviello e Giovanni Di Trapani

Subjects
calamità naturali, innovazione, risk management, assicurazioni
Abstract

Quello dei rischi catastrofali è un tema chiave del dibattito di politica economica del Paese, che mostra emblematicamente come occorre passare dalla "gestione" al "governo" dei rischi. E quindi dal trattamento delle technicalities operative connesse al risk management al cuore stesso della politica economica. La politica infatti per l'economista pubblico, soprattutto italiano, deve fare i conti con la carenza delle risorse finanziarie e strumentali, con le distorsioni indotte dall'intervento pubblico, con l'inefficienza la burocrazia e spesso la corruzione degli apparati. Questo è ancora più vero nel caso delle calamità naturali, rispetto a cui la domanda di politiche pubbliche appare oggi in crescita drammatica. L'analisi delle tendenze in atto mostra quanto siano vulnerabili rispetto a questi accadimenti l'intera società e la sua economia, e quanto questa vulnerabilità sia crescente. D'altro canto la domanda di protezione è anch'essa aumentata significativamente. Per questi motivi è apparso essenziale rivisitare l'intero approccio al problema e sviluppare strategie efficienti per mitigare e gestire finanziariamente i rischi derivanti dalle catastrofi. E' sembrato ineludibile adottare una logica di sistema, di "sistema-Paese". Qui entra in gioco il ruolo del settore privato, e in particolare dell'industria del risparmio assicurativo. Proprio l'OCSE, tra le buone pratiche di mitigazione e finanziamento dei rischi catastrofali , invita gli Stati a considerare il ricorso all'infrastruttura assicurativa esistente in ogni paese, come uno strumento fondamentale da rendere operativo in funzione della copertura dei rischi e dell'intervento di sostegno.

Published
2016

19. Remote third shift EAST operation: a new paradigm

Author

Schissel, D.P., primary, Coviello, E., additional, Eidietis, N., additional, Flanagan, S., additional, Garcia, F., additional, Humphreys, D., additional, Kostuk, M., additional, Lanctot, M., additional, Lee, X., additional, Margo, M., additional, Miller, D., additional, Parker, C., additional, Penaflor, B., additional, Qian, J.P., additional, Sun, X., additional, Tan, H., additional, Walker, M., additional, Xiao, B., additional, and Yuan, Q., additional

Published
2017
Full Text
View/download PDF

21. Cancer incidence in Italian contaminated sites

Author

Comba, P., Ricci, P., Iavarone, I., Pirastu, R., Buzzoni, C., Fusco, M., Ferretti, S., Fazzo, L., Pasetto, R., Zona, A., Crocetti, E., Autelitano, M., Beccaloni, E., Benedetti, M., Benfatto, L., Biggeri, A., Binazzi, A., Bianconi, F., Bidoli, E., Bruno, C., Candela, G., Carere, M., Catelan, D., Cocchioni, Mario, Conti, S., Corfiati, M., Coviello, E., Cremone, L., Dei Tos, A. P., De Santis, M., Falcini, F., Falleni, F., Federico, M., Giacomin, A., Gola, G., Grisotto, L., Guzzinati, S., La Rosa, F., Lillini, L., Madeddu, A., Magoni, M., Mangone, L., Manno, V., Marcello, I., Marinaccio, A., Marsili, G., Maspero, S., Maule, M., Mazzoleni, G., Merletti, F., Minelli, G., Minerba, A., Michiara, M., Nicita, C., Pannozzo, F., Piccardi, A., Piffer, S., Pisani, P., Santoro, M., Scaini, F., Sciacca, S., Sechi, O., Serraino, D., Soggiu, M. E., Stracci, F., Sutera Sardo, A., Tagliabue, G., Tisano, F., Usala, M., Vercelli, M., Vitale, F., Vitarelli, Susanna, and Zambon, P.

Published
2014

22. Cancer incidence in Italian contaminated sites

Author

Comba, Pietro, Ricci, Paolo, Iavarone, Ivano, Pirastu, Roberta, Buzzoni, Carlotta, Fusco, Mario, Ferretti, Stefano, Fazzo, Lucia, Pasetto, Roberto, Zona, Amerigo, Crocetti, Emanuele, Autelitano, M., Beccaloni, E., Benedetti, M., Benfatto, L., Biggeri, A., Binazzi, Alice, Bianconi, F., Bidoli, E., Bruno, C., Candela, G., Carere, M., Catelan, D., Cocchioni, M., Conti, S., Corfiati, M., Coviello, E., Cremone, L., Dei Tos, A. P., De Santis, M., Falcini, F., Falleni, F., Federico, M., Giacomin, A., Gola, G., Grisotto, L., Guzzinati, S., La Rosa, F., Lillini, L., Madeddu, A., Magoni, M., Mangone, L., Manno, V., Marcello, I., Marinaccio, A., Marsili, G., Maspero, S., Maule, M., Mazzoleni, G., Merletti, F., Minelli, GIAN MARIA, Minerba, A., Michiara, M., Nicita, C., Pannozzo, Francesca, Piccardi, Andrea, Piffer, Stefano, Pisani, P., Santoro, M., Scaini, F., Sciacca, S., Sechi, O., Serraino, D., Soggiu, M. E., Stracci, F., SUTERA SARDO, Alessandro, Tagliabue, G., Tisano, F., Usala, M., Vercelli, M., Vitale, F., Vitarelli, S., and Zambon, P.

Subjects
Contaminated sites, Cancer incidence, Environmental pollution, Public Health, Environmental and Occupational Health
Published
2014

24. Alphasat Aldo Paraboni payload IOT campaign and status after the first year of operation

Author

Di Cola, F., primary, Pandolfi, A., additional, Di Paolo, G., additional, Rivera, J., additional, Benzi, E., additional, Martellucci, A., additional, Schmidt, M., additional, Ebert, J., additional, Cuervo, F., additional, Falzini, S., additional, Salaris, P., additional, Coviello, E., additional, De Viti, E., additional, Riva, C., additional, Luini, L., additional, Codispoti, G., additional, Russo, E., additional, and Parca, G., additional

Published
2016
Full Text
View/download PDF

25. [Survival for all cancers is increasing, especially in men, but only thanks to PSA]

Author

Coviello, E, Rashid, I, Buzzoni, C, Fusco, M, Bisanti, L, Sechi, O, Candela, G, Crosignani, P, De Lisi, V, Donato, A, Mangoni, M, Falcini, F, Federico, Massimo, Gennaro, V, Giacomin, A, La Rosa, F, Madeddu, A, Contrino, Ml, Mangone, L, Mazzoleni, G, Pannozzo, F, Zanetti, R, Cocchioni, M, Piffer, S, Pisani, P, PONZ DE LEON, Maurizio, Ricci, P, Serraino, D, Sutera, A, Tessandori, R, Traina, A, Tumino, R, Usala, M, Vercelli, M, Vitarelli, S, Zambon, P, Crocetti, E, Ferretti, S, Gola, G, and Sciacca, S.

Subjects
Male, Survival Rate, PSA, Sex Factors, Italy, Neoplasms, prostate cancer survival, Humans, Prostatic Neoplasms, Female, Prostate-Specific Antigen, survival
Published
2013

29. Italian cancer figures, report 2011: Survival of cancer patients in Italy

Author

Fusco, M, Buzzoni, C, Coviello, E, Rashid, I, Bianconi, F, Cuccaro, F, Castaing, M, De Angelis, R, Giacomin, A, Guzzinati, S, Mosso, Ml, Pisani, P, Quaglia, A, Randi, G, Ramazzotti, V, Russo, A, Senatore, G, Stracci, F, Traina, A, Vercelli, M, Zarcone, M, Ferretti, S, Mazzoleni, G, Bellú, F, Tschugguel, B, De Valiere, E, Facchinelli, G, Falk, M, Dal Cappello, T, Vercellino, Pc, Andreone, S, Busato, A, Marzola, L, Migliari, E, Carletti, N, Nenci, I, Crocetti, E, Caldarella, A, Corbinelli, A, Giusti, F, Intrieri, T, Manneschi, G, Nemcova, L, Romeo, G, Sacchettini, C, Zappa, M, Paci, E, Serraino, D, Angelin, T, Bidoli, E, Dal Maso, L, de Dottori, M, De Paoli, A, De Santis, E, Forgiarini, O, Lise, M, Zucchetto, A, Zanier, L, Orengo, Ma, Casella, C, Marani, E, Puppo, A, Celesia, Mv, Cogno, R, Manenti, S, Garrone, E, Pannozzo, F, Busco, S, Cercato, Mc, Battisti, W, Sperduti, I, Macci, L, Bugliarello, E, Bernazza, E, Tamburo, L, Rossi, M, Curatella, S, De Francesco, C, Tamburrino, S, Bisanti, L, Autelitano, M, Ghilardi, S, Leone, R, Filipazzi, L, Bonini, A, Giubelli, C, Federico, M, Artioli, Me, Valla, K, Braghiroli, B, Cirilli, C, Luminari, S, Pirani, M, Ferrari, L, Bellatalla, C, Panico, M, Perrotta, C, Vassante, B, Vitale, Mf, Michiara, M, Bozzani, F, Sgargi, P, Tumino, R, La Rosa MG, Cascone, G, Frasca, G, Giurdanella, Mc, Martorana, C, Morana, G, Nicita, C, Rollo, Pc, Ruggeri, Mg, Sigona, A, Spata, E, Vacirca, S, Mangone, L, Di Felice, E, Pezzarossi, A, Caroli, S, Pellegri, C, Vicentini, M, Storchi, C, Cavuto, S, Costa, J, Falcini, F, Colamartini, A, Bucchi, L, Balducci, C, Ravegnani, M, Vitali, B, Cordaro, C, Caprara, L, Giuliani, O, Giorgetti, S, Salvatore, S, Palumbo, M, Vattiato, R, Ravaioli, A, Foca, F, Rinaldi, E, Mancini, S, Tonelli, C, Amadori, M, Cremone, L, Iannelli, A, Zevola, A, Budroni, M, Cesaraccio, R, Pirino, D, Carboni, D, Fiori, G, Soddu, M, Mameli, G, Mura, F, Contrino, Ml, Madeddu, A, Tisano, F, Sciacca, S, Muni, A, Mizzi, M, Russo, M, Sacco, G, Aletta, P, Colanino Ziino, A, Tessandori, R, Fanetti, Ac, Maspero, S, Annulli, Ml, Moroni, E, Sanoja Gonzalez ME, Zanetti, R, Rosso, S, Patriarca, S, Prandi, R, Sobrato, I, Gilardi, F, Busso, P, Piffer, S, Gentilini, Ma, Battisti, L, Rizzello, R, Cappelletti, M, Moser, M, La Rosa, F, D'Alò, D, Scheibel, M, Costarelli, D, Spano, F, Rossini, S, Santucci, C, Petrinelli, Am, Solimene, C, Brunori, V, Crosignani, P, Tagliabue, G, Contiero, P, Preto, L, Tittarelli, A, Maghini, A, Codazzi, T, Frassoldi, E, Gada, D, Costa, E, di Grazia, L, Zambon, P, Baracco, M, Bovo, E, Dal Cin, A, Fiore, Ar, Greco, A, Monetti, D, Rosano, A, Stocco, C, Tognazzo, S, Donato, Francesco, Limina, Rosa Maria, Adorni, A, Andreis, P, Zani, G, Piovani, F, Salvi, O, Puleio, M, Vitarelli, S, Antonini, S, Candela, G, Pappalardo, G, Scuderi, T, Lottero, B, Ribaudo, M, Ricci, P, Guarda, L, Gatti, L, Bozzeda, A, Dall'Acqua, M, Pironi, V, Sutera Sardo, A, Mazzei, A, Sirianni, N, Lavecchia, Am, Mancuso, P, Usala, M, Pala, F, Sini, Gm, Pintori, N, Canu, L, Demurtas, G, Doa, N, Ponz de Leon, M, Domati, F, Rossi, G, Goldoni, Ca, Rossi, F, De Gaetani, C, Benatti, P, Roncucci, L, Di Gregorio, C, Pedroni, M, Pezzi, A, Maffei, S, Mariani, F, Borsi, E, Carruba, G, Cusimano, R, Amodio, R, Dolcemascolo, C, Staiti, R, Pastore, G, Magnani, C, Terracini, B, Cena, T, Alessi, D, Baussano, I, Merletti, F, Maule, M, Macerata, V, Cocchioni, M, Pascucci, C, Gennaro, V, Lazzarotto, A, Benfatto, L, Mazzucco, G, and Montanaro, F.

Subjects
Survival, Italy, cancer patients
Published
2011

30. I tumori in Italia. Rapporto 2011: La sopravvivenza dei pazienti oncologici in Italia

Author

Fusco M, Airtum Working G. R. O. U. P., Buzzoni, C., Coviello, E., Rashid, I., Bianconi, F., Cuccaro, F., Castaing, M., Angelis, R., Giacomin, A., Guzzinati, S., Mosso, Ml, Pisani, P., Quaglia, A., Randi, G., Ramazzotti, V., Russo, A., Senatore, G., Stracci, F., Traina, A., Vercelli, M., Zarcone, M., Ferretti, S., Mazzoleni, G., Bellú, F., Tschugguel, B., Valiere, E., Facchinelli, G., Falk, M., Dal Cappello, T., Vercellino, Pc, Andreone, S., Busato, A., Marzola, L., Migliari, E., Carletti, N., Nenci, I., Crocetti, E., Caldarella, A., Corbinelli, A., Giusti, F., Intrieri, T., Manneschi, G., Nemcova, L., Romeo, G., Sacchettini, C., Zappa, M., Paci, E., Serraino, D., Angelin, T., Bidoli, E., Dal Maso, L., Dottori, M., Paoli, A., Santis, E., Forgiarini, O., Lise, M., Zucchetto, A., Zanier, L., Orengo, Ma, Casella, C., Marani, E., Puppo, A., Celesia, Mv, Cogno, R., Manenti, S., Garrone, E., Pannozzo, F., Busco, S., Cercato, Mc, Battisti, W., Sperduti, I., Macci, L., Bugliarello, E., Bernazza, E., Tamburo, L., Rossi, M., Curatella, S., Francesco, C., Tamburrino, S., Bisanti, L., Autelitano, M., Ghilardi, S., Leone, R., Filipazzi, L., Bonini, A., Giubelli, C., Federico, Massimo, Artioli, Me, Valla, K., Braghiroli, B., Cirilli, C., stefano luminari, Pirani, M., Ferrari, L., Bellatalla, C., Fusco, M., Panico, M., Perrotta, C., Vassante, B., Vitale, Mf, Michiara, M., Bozzani, F., Sgargi, P., Tumino, R., La Rosa MG, Cascone, G., Frasca, G., Giurdanella, Mc, Martorana, C., Morana, G., Nicita, C., Rollo, Pc, Ruggeri, Mg, Sigona, A., Spata, E., Vacirca, S., Mangone, L., Di Felice, E., Pezzarossi, A., Caroli, S., Pellegri, C., Vicentini, M., Storchi, C., Cavuto, S., Costa, J., Falcini, F., Colamartini, A., Bucchi, L., Balducci, C., Ravegnani, M., Vitali, B., Cordaro, C., Caprara, L., Giuliani, O., Giorgetti, S., Salvatore, S., Palumbo, M., Vattiato, R., Ravaioli, A., Foca, F., Rinaldi, E., Mancini, S., Tonelli, C., Amadori, M., Cremone, L., Iannelli, A., Zevola, A., Budroni, M., Cesaraccio, R., Pirino, D., Carboni, D., Fiori, G., Soddu, M., Mameli, G., Mura, F., Contrino, Ml, Madeddu, A., Tisano, F., Sciacca, S., Muni, A., Mizzi, M., Russo, M., Sacco, G., Aletta, P., Colanino Ziino, A., Tessandori, R., Fanetti, Ac, Maspero, S., Annulli, Ml, Moroni, E., Sanoja Gonzalez ME, Zanetti, R., Rosso, S., Patriarca, S., Prandi, R., Sobrato, I., Gilardi, F., Busso, P., Piffer, S., Gentilini, Ma, Battisti, L., Rizzello, R., Cappelletti, M., Moser, M., La Rosa, F., D Alò, D., Scheibel, M., Costarelli, D., Spano, F., Rossini, S., Santucci, C., Petrinelli, Am, Solimene, C., Brunori, V., Crosignani, P., Tagliabue, G., Contiero, P., Preto, L., Tittarelli, A., Maghini, A., Codazzi, T., Frassoldi, E., Gada, D., Costa, E., Di Grazia, L., Zambon, P., Baracco, M., Bovo, E., Dal Cin, A., Fiore, Ar, Greco, A., Monetti, D., Rosano, A., Stocco, C., Tognazzo, S., Donato, F., Limina, Rm, Adorni, A., Andreis, P., Zani, G., Piovani, F., Salvi, O., Puleio, M., Vitarelli, S., Antonini, S., Candela, G., Pappalardo, G., Scuderi, T., Lottero, B., Ribaudo, M., Ricci, P., Guarda, L., Gatti, L., Bozzeda, A., Dall Acqua, M., Pironi, V., Sutera Sardo, A., Mazzei, A., Sirianni, N., Lavecchia, Am, Mancuso, P., Usala, M., Pala, F., Sini, Gm, Pintori, N., Canu, L., Demurtas, G., Doa, N., Maurizio Ponz de Leon, Domati, Federica, Rossi, Giuseppina, Goldoni, Ca, Rossi, F., Gaetani, C., Piero Benatti, Luca Roncucci, Di Gregorio, C., Pedroni, Monica, Pezzi, A., Maffei, Stefania, Mariani, Francesco, Borsi, E., Carruba, G., Cusimano, R., Amodio, R., Dolcemascolo, C., Staiti, R., Pastore, G., Magnani, C., Terracini, B., Cena, T., Alessi, D., Baussano, I., Merletti, F., Maule, M., Macerata, V., Cocchioni, M., Pascucci, C., Gennaro, V., Lazzarotto, A., Benfatto, L., Mazzucco, G., and Montanaro, F.

Subjects
Survival, cancer
Published
2011

32. Hemochromatosis in Italy in the last 30 years: role of genetic and acquired factors

Author

Fracanzani, A, Piperno, A, Valenti, L, Fraquelli, M, Coletti, S, Maraschi, A, Consonni, D, Coviello, E, Conte, D, Fargion, S, Fracanzani, AL, Fargion, S., PIPERNO, ALBERTO, COLETTI, SABINA, Fracanzani, A, Piperno, A, Valenti, L, Fraquelli, M, Coletti, S, Maraschi, A, Consonni, D, Coviello, E, Conte, D, Fargion, S, Fracanzani, AL, Fargion, S., PIPERNO, ALBERTO, and COLETTI, SABINA

Abstract

The clinical presentation of hereditary hemochromatosis has changed markedly in recent years. The aim of this study was to analyze a large series of consecutive Italian patients with hemochromatosis diagnosed between 1976 and 2007 to determine whether the genetic background and the presence of acquired risk factors influenced the severity of iron overload and the natural history of the disease. A cohort of 452 Italian patients with iron overload-338 HFE-related (C282Y homozygotes or compound C82Y/H63D heterozygotes) and 114 non-HFE-related-were followed prospectively for a median of 112 months. Alcohol intake, smoking habits, and iron removed to depletion were similar in patients with and without HFE-related iron overload. Hepatitis B virus (4% and 9%; P = 0.04) and hepatitis C virus (6% and 19%; P = 0.002) infections were more frequent in patients with non-HFE-related iron overload. Seventy-three percent of patients with HFE and 61% of patients with non-HFE-related disease had no acquired risk factor. Cirrhosis was significantly more frequent in non-HFE patients independent of the presence of acquired risk factors (P = 0.02). Sex, alcohol intake, prevalence of smoking, hepatitis C virus infection, glucose, lipids, iron-related parameters, and prevalence of C282Y/H63D differed significantly over the years. At enrollment, cirrhosis was present in 145 cases and was significantly more frequent in the first decade (80%, 47%, and 13%; P = 0.001). Survival did not differ across the decades in cirrhotic patients; hepatocellular carcinoma occurred similarly in HFE and non-HFE patients. CONCLUSION: Patients with HFE and non-HFE-related iron overload have comparable iron overload and similar clinical history. Patients who were diagnosed during the last 10 years and were not identified as cirrhotic at enrollment have less severe disease and lower prevalence of acquired risk factors, independent of genetic background

Published
2010

48. Clustering hidden Markov models with variational HEM

Author

Coviello, E., Antoni B. CHAN, and Lanckriet, G. R. G.

Subjects
FOS: Computer and information sciences, Computer Science - Learning, Statistics - Machine Learning, Computer Vision and Pattern Recognition (cs.CV), Computer Science - Computer Vision and Pattern Recognition, Machine Learning (stat.ML), Machine Learning (cs.LG)
Abstract

The hidden Markov model (HMM) is a widely-used generative model that copes with sequential data, assuming that each observation is conditioned on the state of a hidden Markov chain. In this paper, we derive a novel algorithm to cluster HMMs based on the hierarchical EM (HEM) algorithm. The proposed algorithm i) clusters a given collection of HMMs into groups of HMMs that are similar, in terms of the distributions they represent, and ii) characterizes each group by a "cluster center", i.e., a novel HMM that is representative for the group, in a manner that is consistent with the underlying generative model of the HMM. To cope with intractable inference in the E-step, the HEM algorithm is formulated as a variational optimization problem, and efficiently solved for the HMM case by leveraging an appropriate variational approximation. The benefits of the proposed algorithm, which we call variational HEM (VHEM), are demonstrated on several tasks involving time-series data, such as hierarchical clustering of motion capture sequences, and automatic annotation and retrieval of music and of online hand-writing data, showing improvements over current methods. In particular, our variational HEM algorithm effectively leverages large amounts of data when learning annotation models by using an efficient hierarchical estimation procedure, which reduces learning times and memory requirements, while improving model robustness through better regularization., Comment: 44 pages

49. Sentieri-epidemiological study of residents in national priority contaminated sites: Mortality, cancer incidence and hospital discharges,Sentieri-studio epidemiologico nazionale dei territori e degli insediamenti esposti a rischio da inquinamento: Mortalità, incidenza oncologica e ricoveri ospedalieri

Author

Ancona, C., Ascoli, V., Bastone, A., Beccaloni, E., Benedetti, M., Bianchi, F., Biggeri, A., Binazzi, A., Bruno, C., Cadum, E., Caranci, N., Carboni, C., Carere, M., Catelan, D., Cernigliaro, A., Comba, P., Conti, S., Corfiati, M., Demaria, M., Santis, M. D., Falleni, F., Fazzo, L., Forastiere, F., Goldoni, C. A., Grisotto, L., Iavarone, I., Leonardi, M., Manno, V., Marcello, I., Marinaccio, A., Marsili, G., Martuzzi, M., Minelli, G., Minichilli, F., Mitis, F., Musmeci, L., Pasetto, R., Piccardi, A., Pirastu, R., Santoro, M., Scaini, F., Soggiu, M. E., Zona, A., Autelitano, M., Benfatto, L., Bonelli, L., Bianconi, F., Bidoli, E., Buzzoni, C., Candela, G., Cocchioni, M., Coviello, E., Cremone, L., Crocetti, E., Tos, A. P. D., Falcini, F., Federico, M., Ferretti, S., Fusco, M., Giacomin, A., Gola, G., Guzzinati, S., Rosa, F. L., Lillini, R., Madeddu, A., Magoni, M., Mangone, L., Maspero, S., Maule, M., Mazzoleni, G., Merletti, F., Michiara, M., Minerba, S., Nicita, C., Pannozzo, F., Piffer, S., Ricci, P., Carlotta Sacerdote, Sciacca, S., Sechi, O., Serraino, D., Stracci, F., Sardo, A. S., Tagliabue, G., Tisano, F., Usala, M., Vercelli, M., Vitale, F., Vitarelli, S., and Zambon, P.

Catalog

Books, media, physical & digital resources
See catalog results